Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Apple

Costco

Microsoft

NVIDIA

We have narrowed down our search to five U.S. corporate behemoths that have strong growth potential for the rest of 2021. These are: AAPL, MSFT, NVDA, DHR and COST.

Fed Gives Bond-Buy Tapering Signal Without Timeline: 5 Picks

WASHINGTON, Sept. 21, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2021 on Thursday, October 21, 2021 beginning at 8:00 a.m.

Danaher Schedules Third Quarter 2021 Earnings Conference Call

Agilent Technologies

American Water Works

Invesco S&P Global Water Index ETF

Ecolab

Ferguson Enterprises Inc

First Trust Water ETF

Invesco

Invesco Water Resources ETF

Invesco Global Water ETF

Pentair

Roper Technologies

Veolia Environnement SA

Waters

Xylem

An in-depth look at the leading water ETFs in the U.S stock market.

Investing in Water ETFs

Crocs

Sonos

Wendy's

Inside the top-ranked stocks that can beat earnings estimates in their next releases.

Forget Earnings Growth, Focus on Beat With These 5 Stocks

Carrier Global

Motorola Solutions

Republic Services

We have narrowed down our search to five large-cap low-beta stocks that have provided double-digit returns in the past three months. These are: DHR, COST, CARR, MSI, and RSG.

Top 5 High-Flying Low-Beta Stocks for a Volatile September

Editas Medicine

Veeva Systems

These businesses are firing on all cylinders.

3 Red-Hot Healthcare Stocks to Buy in September

Danaher Corporation (NYSE:DHR) is a global science and technology conglomerate.

This Medical Device Stock Has Room to Run

FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX builds on cadence of innovation in biopharma with Biologics Explorer, enabling protein characterization analysis for the ZenoTOF 7600 system

SCIEX Builds on Cadence of Innovation in Biopharma With Biologics Explorer

FRAMINGHAM, Mass.--(BUSINESS WIRE)--SCIEX presents the latest capillary electrophoresis solution, the BioPhase 8800 system, the only multi-capillary system for CE-SDS.

SCIEX Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 System

WASHINGTON , Aug. 30, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today the completion of its acquisition of Aldevron. As previously announced, Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.

Danaher Completes Acquisition of Aldevron

American Tower

Amazon

Comcast

Flowers Foods

Hologic

Manhattan Associates

Visa

If you're into ESG investing and are looking for stocks to buy, Morningstar created a portfolio of ESG mutual funds. Here are 10 solid ideas.

10 Best Stocks to Buy if ESG Investing Is Your Thing

Salesforce

Home Depot

NIKE

Procter & Gamble

Engine No. 1 forced Exxon to give the impact investment group at least two seats on its board. Here are 7 stocks to buy from its new ETF.

7 Stocks to Buy to Cash In on Activist Investor Engine No. 1's New ETF

Danaher (DHR), with a 25% rise in shares in the past three months, benefits from strong demand, solid product offerings and synergies from buyouts. Shareholder-friendly policies add to its appeal.

Danaher (DHR) Stock Rise 25% in 3 Months: What's Driving It?

WASHINGTON, Aug. 25, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Investor and Analyst Meeting on September 9, 2021 beginning at 12:00 p.m. ET. The virtual event will be hosted by Rainer M.

Danaher To Webcast Investor And Analyst Meeting

WASHINGTON, Aug. 24, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced that, effective April 1, 2022, Georgeann F. Couchara will succeed Angela S.

Danaher Announces Human Resources And Accounting Leadership Transition Plans

WASHINGTON, Aug. 20, 2021 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that George M. Sherman, the Company's President & Chief Executive Officer during the years 1990-2001, died earlier this week after an illness.

Danaher Announces Passing of Former President & CEO, George M. Sherman

Crane Company

Carlisle Companies

LSB Industries

This is a good time to be investing in conglomerates.

These 4 Diversified Players Look Interesting Now

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Danaher (DHR).

Time to Focus on Danaher (DHR) for Strong Earnings Growth Potential

Adobe

Alphabet

Johnson & Johnson

Pfizer

COVID-19 cases have spiked recently due to a highly transmissible strain. Here's a list of delta variant stocks that could get a boost as cases continue to ramp up.

6 Stocks to Buy as Delta Variant Cases Surge

Global Water Resources

Essential Utilities

York Water

As climate change forces a dramatic rethink on how we utilize our resources, these water stocks will certainly gain relevance. The post 7 Water Stocks to Buy to Bank on Our Most Precious Resource appeared first on InvestorPlace.

7 Water Stocks to Buy to Bank on Our Most Precious Resource

Analyzing the investment case for buying stock in the high-flying life sciences and diagnostics company.

Is Danaher a Buy in a Post-Pandemic World?

Robert Half Int.

3 Stocks With Price and Earnings Estimate Momentum

Does Danaher (DHR) have what it takes to be a top stock pick for momentum investors? Let's find out.

Danaher (DHR) Is Up 2.28% in One Week: What You Should Know

Intuitive Surgical

Middleby

CROX, ISRG, MIDD, and DHR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2021

Top Ranked Momentum Stocks to Buy for July 28th

Clearfield

First Bancorp

HCA Healthcare

Sleep Number

DHR, CLFD, HCA, FBP, and SNBR qualified as the day's Momentum Picks Using Driehaus Strategy.

5 Top-Ranked Momentum Picks Using Driehaus Strategy

News for Danaher Stock (DHR)